Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma

Camrelizumab (SHR-1210) is a humanized IgG4 monoclonal anti-programmed cell death protein 1 (PD-1) antibody that has been shown to inhibit the binding of PD-1 to PD-L1, thereby blocking the immune escape of various types of cancer, including lung squamous cell carcinoma (LSCC). Reactive cutaneous ca...

Full description

Saved in:
Bibliographic Details
Published in:Experimental hematology & oncology 2022-10, Vol.11 (1), p.1-78, Article 78
Main Authors: Ma, Rong, Wang, Jia-Lin, Wang, Yan-Yang
Format: Article
Language:English
Subjects:
Apoptosis
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Complications and side effects
Correspondence
Development and progression
Endothelium
Immunoglobulin G
Liver cancer
Lung cancer
Medical imaging
Metastasis
Patients
Pneumonia
Radiation
Radiation therapy
Radiotherapy
Reactive cutaneous capillary endothelial proliferation (RCCEP)
Recall
Squamous cell carcinoma
Stereotactic body radiation therapy (SBRT)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Camrelizumab (SHR-1210) is a humanized IgG4 monoclonal anti-programmed cell death protein 1 (PD-1) antibody that has been shown to inhibit the binding of PD-1 to PD-L1, thereby blocking the immune escape of various types of cancer, including lung squamous cell carcinoma (LSCC). Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event in camrelizumab-treated patients. Here, we introduce a case of LSCC with recall RCCEP induced by stereotactic body radiation therapy (SBRT). A 76-year-old LSCC patient developed RCCEP when he received camrelizumab and chemotherapy. After discontinuing camrelizumab treatment, the RCCEP lesions spontaneously regressed and fell off. However, when the patient received subsequent SBRT, the RCCEP occurred again at the same sites. This case may provide clues for additional study of the immune reactivation effect of SBRT or the underlying mechanism of RCCEP.
ISSN:2162-3619
2162-3619
DOI:10.1186/s40164-022-00336-4